CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jan. 28, 2017	Jan. 30, 2016	Jan. 31, 2015
Cash flows from operating activities:
Net loss	$ (66,531)	$ (7,371)	$ (28,904)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	47,027	45,652	41,029
Net gain on asset disposition	(846)	(2,887)	(3,601)
Provision for store closures and asset impairment	25,362	1,376	16,125
Stock-based compensation	8,984	2,262	2,433
Provision (recovery) for uncollectible receivables	(984)	532	1,383
LIFO reserve increase	5,270	7,595	4,734
Deferred income tax benefit	(7,772)	(831)	(13,289)
Income tax charge (benefit) upon exercise of stock options	28	(247)	(1)
Amortization of debt issuance costs	105	154	34
Benefit for postretirement medical	(55)	(45)	(84)
(Increase) decrease in operating assets:
Trade and non-trade receivables	1,059	(2,306)	2,153
Insurance receivables	(69)	(301)	(441)
Inventories	(13,820)	(31,178)	28,404
Other assets	603	2,998	420
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	(29,757)	29,215	16,689
Income taxes receivable	7,175	8,432	(13,683)
Other noncurrent liabilities	(2,856)	(2,197)	10,302
Net cash provided by (used in) operating activities	(27,077)	50,853	63,703
Cash flows from investing activities:
Capital expenditures	(24,452)	(22,954)	(23,308)
Proceeds from asset dispositions	2,619	3,747	4,861
Insurance recoveries for replacement assets	416
Asset acquisitions, net (primarily intangibles)	(12,700)	(16,596)	(37,605)
Acquisition of Reeves-Sain Drug Store, Inc., net of cash		(42,757)
Net cash used in investing activities	(34,117)	(78,560)	(56,052)
Cash flows from financing activities:
Payments of indebtedness and capital lease obligations	(621)	(554)	(2,472)
Proceeds from revolving line of credit	990,965	937,164	455,079
Payments on revolving line of credit	(914,962)	(902,681)	(451,236)
Debt issuance costs	(5,831)	(525)
Excess tax charges (benefit) from stock-based compensation	(28)	247	1
Proceeds (payments) from exercise of stock options and employee stock purchase plan	553	2,462	(462)
Cash dividends paid	(8,969)	(8,929)	(8,846)
Net cash provided by (used in) financing activities	61,107	27,184	(7,936)
Decrease in cash and cash equivalents	(87)	(523)	(285)
Cash and cash equivalents:
Beginning of year	5,917	6,440	6,725
End of year	5,830	5,917	6,440
Supplemental disclosures of cash flow information:
Interest paid	2,318	1,431	504
Income taxes paid (refunded)	(9,906)	(12,911)	8,045
Non-cash investing and financial activities:
Acquisition related note payable, see Note 10 - Indebtedness		$ 13,000